• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

    1.400 UNCHANGED
    Streaming Delayed Price Updated: 3:58 PM EST, Nov 6, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about BioRestorative Therapies, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    EXCLUSIVE: BioRestorative To Receive Third US Patent For Metabolic ThermoStem Program
    The United States Patent and Trademark Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program.  
    Via Benzinga
    BioRestorative Therapies: This Biopharma Company Is Helping Your Body Heal Itself
    Lance Alstodt, Chairman and CEO of BioRestorative Therapies, Inc. (NASDAQ: BRTX), was recently interviewed by Benzinga.  
    Via Benzinga
    BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
    By Julian Richard, Benzinga 
    Via TheNewswire.com
    Topics Intellectual Property
    BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
    BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes 
    Via News Direct
    Topics Intellectual Property
    BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
    BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a... 
    Via Benzinga
    BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program
    Via Investor Brand Network
    Topics Intellectual Property
    EXCLUSIVE: BioRestorative Poised To Receive European Patent For ThermoStem Program
    The European Patent Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program.  The notice of allowance was... 
    Via Benzinga
    BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
    BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results 
    Via News Direct
    BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
    By Julian Richard, Benzinga 
    Via TheNewswire.com
    BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
    Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony... 
    Via Benzinga
    2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
    By Faith Ashmore, Benzinga 
    Via TheNewswire.com
    Topics Intellectual Property
    2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
    2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies 
    Via News Direct
    2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
    BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. 
    Via Benzinga
    BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
    From BioRestorative Therapies, Inc
    Via GlobeNewswire
    EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome
    BioRestorative Therapies Inc (NASDAQ: BRTX) has received a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development... 
    Via Benzinga
    BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
    From BioRestorative Therapies, Inc
    Via GlobeNewswire
    EXCLUSIVE: BioRestorative Therapies Gets Exclusive License Rights From Regenexx For Development Of BRTX-100 Disc Program To Treat Chronic Lumbar Disc Disease
    BioRestorative Therapies, Inc (NASDAQ: BRTX), a stem cell-based therapies clinical-stage company, forged an agreement with Regenexx, LLC, under which BRTX gets exclusive license rights for intellectual... 
    Via Benzinga
    BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference
    Via Investor Brand Network
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
    From BioRestorative Therapies, Inc
    Via GlobeNewswire
    Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
    EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
    Via FinancialNewsMedia
    The NIH Has Given BioRestorative Therapies A Stamp Of Approval
    By Faith Ashmore, Benzinga 
    Via News Direct
    The NIH Has Given BioRestorative Therapies A Stamp Of Approval
    BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes. 
    Via TheNewswire.com
    The NIH Has Given BioRestorative Therapies A Stamp Of Approval
    BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.  
    Via Benzinga
    See What's Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!
    While stem cell therapy has always been a more controversial topic, as the general public has gained more knowledge on the practice and induced pluripotent stem (iPS) cells have gained traction in... 
    Via Benzinga
    BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show
    From BioRestorative Therapies, Inc
    Via GlobeNewswire
    A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
    Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
    Via TheNewswire.com
    A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
    By David Willey, Benzinga 
    Via News Direct
    A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
    Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
    Via Benzinga
    Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
    Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.